Survey Shows Europe's Perception of Biotechnology to be Favorable - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Survey Shows Europe's Perception of Biotechnology to be Favorable


ePT--the Electronic Newsletter of Pharmaceutical Technology

European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem-cell research.

According to the EC, biotechnology is a major driver in the health and well-being of European citizens, but many factors have affected its development, including consumer safety concerns, strong environmental movements, and little social acceptance. The EC’s Eurobarometer survey, however, showed that 80% of Europeans are in favor of, or unopposed to, biotechnology, although there is still a demand for more facts and communication.

Overall, there was great support for medical biotechnology, with 68% of respondents approving of stem-cell research and 63% approving of embryonic stem-cell research. Additionally, 58% of respondents approve of xenotransplantation, which is subject to moratoria in several countries. The support for medical biotechnology also reaches to nontherapeutic applications, with 56% of respondents approving of research aiming to enhance human performance. However, there was also a strong consensus that strict laws will be needed to alleviate concerns about ethical issues.

Biobanks, facilities that store biological samples, were also well supported. Although only one in three respondents had heard about biobanks, nearly one in two said they would definitely or probably participate in them, with Scandinavian countries showing particular enthusiasm. 

“These findings are very encouraging,” Nathalie Moll, secretary general of the European Association for Bioindustries (EuropaBio), said in a press statement. “They show that Europeans increasingly understand and appreciate the benefits that biotechnology brings... In particular, we are delighted by the overwhelming support for medical biotechnology and for the strong support shown for crop-based and nonfood based biofuels.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here